# Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

> **NCT00438659** · PHASE3 · COMPLETED · sponsor: **North Central Cancer Treatment Group** · enrollment: 176 (actual)

## Conditions studied

- Breast Cancer
- Dermatologic Complications
- Radiation Toxicity
- Skin Reactions Secondary to Radiation Therapy

## Interventions

- **DRUG:** mometasone furoate
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00438659
- **Lead sponsor:** North Central Cancer Treatment Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-01
- **Final completion:** 2014-06
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2016-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00438659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00438659, "Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00438659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*